FDG PET/CT for evaluating systemic arterial inflammation induced by anthracycline-based chemotherapy of Hodgkin lymphoma: A retrospective cohort study

• Published in: Medicine (Baltimore) Vol. 99; no. 48; p. e23259
• Main Authors: Lawal, Ismaheel O, Orunmuyi, Akintunde T, Popoola, Gbenga O, Lengana, Thabo, Mokoala, Kgomotso M G, Ankrah, Alfred O, Sathekge, Mike M
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 25-11-2020
• Subjects: Adult; Anthracyclines - adverse effects; Anthracyclines - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Arteritis - chemically induced; Arteritis - diagnostic imaging; Arteritis - metabolism; Cardiovascular Diseases - epidemiology; Female; Fluorodeoxyglucose F18 - metabolism; HIV Infections - epidemiology; Hodgkin Disease - drug therapy; Humans; Hypertension - epidemiology; Male; Observational Study; Positron Emission Tomography Computed Tomography - methods; Radiopharmaceuticals - metabolism; Retrospective Studies; Risk Factors; Smoking - epidemiology
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000023259

To evaluate arterial fluorodeoxyglucose (FDG) uptake as a marker of arterial inflammation in multiple vascular beds in patients treated with anthracycline-based chemotherapy for Hodgkin lymphoma (HL).We used maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR) to quantify arterial FDG uptake in the carotid artery, ascending aorta, abdominal aorta, and femoral artery obtained on positron emission tomography/computed tomography (PET/CT) imaging performed at baseline before chemotherapy and after completion of chemotherapy in patients with HL treated with an anthracycline-containing regimen. We compared the SUVmax and TBR obtained at baseline with that obtained post-chemotherapy for each arterial bed to evaluate the effect of anthracycline-based chemotherapy. We evaluated the effect of cardiovascular risk factors such as human immunodeficiency virus (HIV) infection, smoking, hypertension, and diabetes on the changes in SUVmax and TBR seen in the different arterial beds after anthracycline-based chemotherapy.Fifty-two patients were included with a mean age of 34.56 ± 10.19 years. There were 33 males, and 18 patients were HIV-infected. The mean interval between completion of chemotherapy and follow-up flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) scan was 65 weeks. We found no significant difference in arterial FDG uptake measured by SUVmax and TBR in all arterial beds between the pre- and post-chemotherapy FDG PET/CT. There was no significant impact of HIV infection, smoking, and hypertension on the changes in arterial FDG uptake following treatment with anthracycline-based chemotherapy.In patients with HL who were treated with anthracycline-based chemotherapy, we found no significant increase in arterial inflammation measured by FDG PET/CT after an average follow-up period of about 65 weeks since completion of chemotherapy.